Effect of valproic acid on behavior and plasma amino acid concentrations in chronic schizophrenic patients

Ko, Grant N.; Korpi, Esa R.; Freed, William J.; Zalcman, Steven; Bigelow, Llewellyn B.

doi:10.1016/0006-3223(85)90085-x

Cited by 27 publications

(11 citation statements)

References 19 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In a recent double-blind, randomized study of 249 schizophrenic patients admitted for acute exacerbation of symptoms, the combination of valproate added to risperidone or olanzapine produced a more rapid response than antipsychotic monotherapy; however, the difference in response between groups diminished over time and was no longer significant by week 4 of treatment (Citrome et al 2004;Casey et al 2003). In contrast, three controlled studies found no therapeutic benefit of valproate adjunctive therapy in chronic, treatment-refractory patients (Ko et al 1985;Dose et al 1998;Hesslinger et al 1999;Basan and Leucht 2004). Another anticonvulsant, carbamazepine, was found to improve symptoms when added to antipsychotic medication in patients with schizophrenia who had EEG abnormalities (Neppe 1983).…”

Section: Clinical and Experimental Medicine Findings With Lamotriginementioning

confidence: 98%

The potential role of lamotrigine in schizophrenia

2005

View full text Add to dashboard Cite

The efficacy of lamotrigine is most likely explained within the framework of a glutamate neuron dysregulation hypothesis, and may arise primarily through the drugs ability to influence glutamate transmission and neural activity in the cortex. The drug is likely to act through inhibition of voltage-gated sodium channels, though other molecular interactions cannot be ruled out. Lamotrigine may add to or synergise with some atypical antipsychotic drugs acting on glutamate transmission; alternatively, they may act independently on glutamate and dopamine systems to bring about a combined therapeutic effect. We propose new strategies for the treatment of schizophrenia using a combination of anti-dopaminergic and anti-glutamatergic drugs.

show abstract

Section: Clinical and Experimental Medicine Findings With Lamotriginementioning

confidence: 98%

The potential role of lamotrigine in schizophrenia

2005

View full text Add to dashboard Cite

show abstract

“…The above randomized studies enrolled relatively small numbers of subjects and included different types of patients-chronic or neuroleptic-resistant patients in two reports 94,97 and acute patients in the other three. 74,95,96 There is recent report, however, of a large (n = 249), multicenter, randomized, double-blind, 28-day clinical trial of adjunctive divalproex in hospitalized patients with an acute exacerbation of schizophrenia.…”

Section: Combination Of Second-generation Antipsychotics and Classic mentioning

confidence: 99%

Toward Convergence in the Medication Treatment of Bipolar Disorder and Schizophrenia

Citrome¹,

Goldberg

Stahl

2005

Harvard Review of Psychiatry

View full text Add to dashboard Cite

Reaching a correct differential diagnosis among patients with psychotic symptoms was especially important during the era of first-generation antipsychotics, when treatments for the different disorders varied in terms of adverse events and likelihood of response. The historical "overdiagnosis" of schizophrenia and "underdiagnosis" of bipolar disorder in the United States was blamed for an increased exposure to neuroleptics among patients who might have benefited from lithium. With the recognition that second-generation antipsychotics are useful in the treatment of both schizophrenia and bipolar mania, and that combining them with classic mood stabilizers such as valproate may results in increased efficacy, the field is witnessing a convergence of pharmacological approaches to the treatment of schizophrenia and bipolar disorder. Substantially more data is available regarding combination treatments for bipolar disorder than for schizophrenia, and appropriate diagnosis remains important in predicting prognosis, but until the precise pathophysiology of psychotic disorders can be elucidated, and specific targeted treatments crafted, we will continue to see similar blended treatments for these two disease states.

show abstract

“…Moreover, it was reported that valproate suppresses the frequency of spontaneous neuronal discharges in the presence of blockade of GABAergic inhibition with biculline (Albus and Williamson, 1998). Also, it appears as if a GABA increase in the brain is only observed at supratherapuetic doses (Sawaya et al, 1975;Löscher, 1981;Ko et al, 1985). Accordingly, it seems currently not very likely that GABAergic transmission is involved in the psychotropic action of valproate, which may also explain the low sedative effect of valproate in the therapeutic range.…”

Section: Sirmentioning

confidence: 99%

Valproate and GABAergic System Effects

Winterer¹

2003

Neuropsychopharmacol

View full text Add to dashboard Cite

Effect of valproic acid on behavior and plasma amino acid concentrations in chronic schizophrenic patients

Cited by 27 publications

References 19 publications

The potential role of lamotrigine in schizophrenia

The potential role of lamotrigine in schizophrenia

Toward Convergence in the Medication Treatment of Bipolar Disorder and Schizophrenia

Valproate and GABAergic System Effects

Contact Info

Product

Resources

About